Percutaneous Implantation of the CoreValve Self-expanding Valve Prosthesis in Patients With Severe Aortic Stenosis and Porcelain Aorta: Medium-term Follow-up |
| |
Authors: | Isaac Pascual Pablo Avanzas Antonio J Muñoz-García Diego López-Otero Manuel F Jimenez-Navarro Belén Cid-Alvarez Raquel del Valle Juan H Alonso-Briales Raimundo Ocaranza-Sanchez Fernando Alfonso José M Hernández Ramiro Trillo-Nouche César Morís |
| |
Institution: | 1. Sección de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain;2. Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, Málaga, Spain;3. Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain;4. Servicio de Cardiología, Hospital Clínico San Carlos, Madrid, Spain |
| |
Abstract: | Introduction and objectivesThere is little information on the use of transcatheter aortic valve implantation in patients with severe aortic stenosis and porcelain aorta. The primary aim of this study was to analyze death from any cause after CoreValve® implantation in patients with severe aortic stenosis, with and without porcelain aorta.MethodsIn this multicenter, observational prospective study, carried out in 3 hospitals, percutaneous aortic valves were implanted in 449 patients with severely calcified aortic stenosis. Of these, 36 (8%) met the criteria for porcelain aorta. The primary end-point was death from any cause at 2 years.ResultsPatients with porcelain aorta more frequently had extracardiac vascular disease (11 30.6%] vs 49 11.9%]; P=.002), prior coronary revascularization (15 41.7%] vs 98 23.7%]; P=.017), and dyslipidemia (26 72.2%] vs 186 45%]; P=.02). In these patients, there was greater use of general anesthesia (15 41.7%] vs 111 16.9%]; P=.058) and axillary access (9 25%] vs 34 8.2%]; P=.004). The success rate of the procedure (94.4 vs 97.3%; P=.28) and the incidence of complications (7 19.4%] vs 48 11.6%]; P=.20) were similar in both groups. There were no statistically significant differences in the primary end point at 24 months of follow-up (8 22.2%] vs 66 16%]; P=.33). The only predictive variable for the primary end point was the presence of complications during implantation (hazard ratio=2.6; 95% confidence interval, 1.5-4.5; P=.001).ConclusionsIn patients with aortic stenosis and porcelain aorta unsuitable for surgery, percutaneous implantation of the CoreValve® self-expanding valve prosthesis is safe and feasible. |
| |
Keywords: | AoP porcelain aorta TAVI transcatheter aortic valve implantation |
本文献已被 ScienceDirect 等数据库收录! |
|